Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease. Its REMaster technology platform identifies and targets key RNA processing steps to modulate gene expression, offering a novel approach to treating diseases. The company's lead candidate, REM-422, is expected to enter Phase 1 clinical studies in 2024.
Buy Funded Startups lists
Funding Round:
Funding Amount: $60M
Date: 03-Jan-2024
Investors: The Column Group, Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Surveyor (a Citadel company), WTT Investment, Willett Advisors
Markets: Biotechnology, RNA Processing, Therapeutics, Health Care, Medical, Drug Discovery, Life Sciences, Oncology
HQ: Watertown, Massachusetts, United States
Founded: 2019
Website: https://www.remixtx.com
LinkedIn: https://www.linkedin.com/company/remix-therapeutics
Twitter: https://twitter.com/remixthera
Crunchbase: https://www.crunchbase.com/organization/remix-therapeutics
Leave a Comment
Comments
No comments yet.